News
02.07.2015 | Company News
BIIB054 reached significant milestone20.03.2015 | Press Release
BIOGEN IDEC PRESENTS POSITIVE INTERIM RESULTS FROM PHASE 1B STUDY AT 2015 AD/PD CONFERENCE05.01.2015 | Company News
Christoph Hock nominated as VP at the University of Zurich06.12.2013 | Press Release
ALS Therapy Development Institute and Neurimmune Partner to Advance Treatments for ALS17.04.2013 | Company News
Human-Derived SOD1 Antibodies Show Promise in ALS Mice05.11.2012 | Company News
Biogen Idec began a double-blind, placebo-controlled Phase Ib trial01.01.2012 | Company News
Neurimmune acquires USD 1.9m funding from Swiss CTI06.04.2011 | Company News
Biogen Idec submitted an investigational new drug (IND) application10.03.2011 | Company News
Neurimmune introduced BIIB03720.12.2010 | Press Release
Biogen Idec and Neurimmune announce agreement on three neurodegenerative disease programs